3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
21
Terminated
7
Active not recruiting
2
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
32
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Recurrence
4
Immunoglobulin Light-chain Amyloidosis
4
Neoplasms, Plasma Cell
3
Hematologic Neoplasms
3
Renal Insufficiency
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
beta-Thalassemia
1
Waldenstrom Macroglobulinemia
1
Thalassemia
1
Plasmablastic Lymphoma
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Leukemia, Plasma Cell
1
Leukemia, Biphenotypic, Acute
1
Burkitt Lymphoma
1
Anemia, Sickle Cell
1
Amyloidosis
1
Acute-Phase Reaction
1
Interventions
Rituximab
7
zanubrutinib
6
venetoclax
4
ibrutinib
3
Dexamethasone
3
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
Blood Specimen Collection
2
Biopsy
2
Bendamustine Hydrochloride
2
pirtobrutinib
1
obinutuzumab
1
Positron-Emission Tomography
1
Lenalidomide
1
Exercise
1
Diet
1
CT-P10
1
Bortezomib
1
ARQ531
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Waldenstrom Macroglobulinemia
×
Bortezomib
×
Clear all
NCT03697356
2023-10-06
Ballondor
Kosin University Gospel Hospital
Phase 2
Recruiting
54 enrolled